Caribou Biosciences CRBU 深 沪
已收盘 12-19 16:00:00 美东时间
1.68
+0.050
+3.07%
华盛通- 最 高1.9699
- 今 开1.63
- 成交量 183.56万股
- 最 低 1.62
- 昨 收 1.63
- 总市值 1.02亿
- 52周最高 3.53
- 市盈率 静 --
- 换手率 3.02%
- 52周最低 0.66
- 委 比 -67.87%
- 总股本 6070.54万
- 历史最高 32.645
- 量 比 1.72
- 振 幅 21.47%
- 历史最低 0.66
- 每 手 1
- 风险率 0.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference
Caribou Biosciences' CEO, Rachel Haurwitz, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4th at 9:20 AM EDT. More details and a webcast link are available on Caribou's website.
05-28 20:00
Caribou Biosciences Q4 2024 GAAP EPS $(0.39) Beats $(0.42) Estimate, Sales $2.08M Miss $2.11M Estimate
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.42) by 7.14 percent. This is unchanged from the same period last year. The company
03-11 04:12
Caribou Biosciences To Present Preclinical Data Supporting Development Of CB-010 For Lupus At The American College Of Rheumatology Convergence 2024
Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract has been accepted for a poster presentation at the American College of
2024-09-25 21:13
Caribou Biosciences CFO Jason O'Byrne Resigns
05:55 PM EDT, 09/03/2024 (MT Newswires) -- Caribou Biosciences (CRBU) said Tuesday that Chief Financial Officer Jason O'Byrne is leaving the company on Sept. 27. The company plans to appoint Ryan Fischesser, vice president of finance and control, as the principal accounting officer after Byrne leave...
2024-09-04 05:55
Caribou Biosciences CFO Jason O'Byrne Informed Of Intent To Resign On Sept 1
Caribou Biosciences CFO Jason O'Byrne Informed Of Intent To Resign On Sept 1
2024-09-04 04:04
Expert Ratings For Caribou Biosciences
Ratings for Caribou Biosciences (NASDAQ:CRBU) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days an...
2024-09-04 01:00
Caribou Biosciences Announces The FDA Has Granted Fast Track Designations To CB-010 In Refractory SLE And To CB-012 In Relapsed Or Refractory AML
Caribou Biosciences Announces The FDA Has Granted Fast Track Designations To CB-010 In Refractory SLE And To CB-012 In Relapsed Or Refractory AML
2024-09-03 20:25
